All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group
EquityABBs-Block Trades

Autolus Therapeutics taps investors for $100m


Autolus Therapeutics, the UK biopharmaceutical company focused on T cell therapies for cancer, is raising additional capital on the Nasdaq.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree